• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Impairment in functional status and survival in patients with acute myeloid leukaemia.急性髓系白血病患者的功能状态损害与生存情况
J Cancer Res Clin Oncol. 2006 Oct;132(10):665-71. doi: 10.1007/s00432-006-0115-7. Epub 2006 Jul 5.
2
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.对早期预后不良或晚期霍奇金淋巴瘤患者,比较包括强化BEACOPP方案的一线化疗与包括ABVD方案的化疗。
Cochrane Database Syst Rev. 2017 May 25;5(5):CD007941. doi: 10.1002/14651858.CD007941.pub3.
3
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.未治疗的霍奇金淋巴瘤患者化疗和放疗在第二原发性恶性肿瘤、总生存期和无进展生存期方面的优化:个体参与者数据分析
Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2.
4
Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia.阿糖胞苷的药物基因组学与急性髓系白血病儿童及青年患者的预后
JAMA Netw Open. 2025 Jun 2;8(6):e2516296. doi: 10.1001/jamanetworkopen.2025.16296.
5
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
6
Thrombopoietin mimetics for patients with myelodysplastic syndromes.用于骨髓增生异常综合征患者的血小板生成素模拟物。
Cochrane Database Syst Rev. 2017 Sep 30;9(9):CD009883. doi: 10.1002/14651858.CD009883.pub2.
7
Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission.白细胞介素-2作为首次完全缓解的儿童和成人急性髓细胞白血病的维持治疗。
Cochrane Database Syst Rev. 2015 Nov 6;2015(11):CD010248. doi: 10.1002/14651858.CD010248.pub2.
8
A systematic overview of chemotherapy effects in acute myeloid leukaemia.急性髓系白血病化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):231-52. doi: 10.1080/02841860151116321.
9
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
10
Occupational therapy for cognitive impairment in stroke patients.脑卒中患者认知障碍的作业治疗。
Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD006430. doi: 10.1002/14651858.CD006430.pub3.

引用本文的文献

1
The Role of the Lawton Instrumental Activities of Daily Living (IADL) Scale in Predicting Adverse Events and Outcomes of R-CHOP Treatment in Elderly Patients with Diffuse Large B-Cell Lymphomas (DLBCLs) or Mantle Cell Lymphomas (MCLs): A Prospective Single-Center Study.洛顿日常生活工具性活动(IADL)量表在预测老年弥漫性大B细胞淋巴瘤(DLBCL)或套细胞淋巴瘤(MCL)患者接受R-CHOP治疗的不良事件和结局中的作用:一项前瞻性单中心研究。
Cancers (Basel). 2024 Dec 14;16(24):4170. doi: 10.3390/cancers16244170.
2
A proposed multi-domain, digital model for capturing functional status and health-related quality of life in oncology.提出了一种多领域的数字模型,用于捕捉肿瘤学中的功能状态和与健康相关的生活质量。
Clin Transl Sci. 2024 Jan;17(1):e13712. doi: 10.1111/cts.13712.
3
Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).异基因造血细胞移植前可测量残留病(MRD)状态对继发性急性髓系白血病结局的影响。来自欧洲血液和骨髓移植学会(EBMT)急性白血病工作组(ALWP)的研究。
Bone Marrow Transplant. 2022 Oct;57(10):1556-1563. doi: 10.1038/s41409-022-01748-w. Epub 2022 Jul 14.
4
The Prognostic Value of Sarcopenia in Acute Myeloid Leukemia Patients and the Development and Validation of a Novel Nomogram for Predicting Survival.肌肉减少症在急性髓系白血病患者中的预后价值及一种预测生存的新型列线图的开发与验证
Front Oncol. 2022 Feb 10;12:828939. doi: 10.3389/fonc.2022.828939. eCollection 2022.
5
Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review.老年 AML 患者的年龄、功能状态和合并症对生活质量和结局的影响:综述。
Ann Hematol. 2021 Jun;100(6):1359-1376. doi: 10.1007/s00277-020-04375-x. Epub 2021 Apr 2.
6
Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.采用简化多维老年评估对 91 例老年 AML 患者进行强化诱导化疗的可行性和结果的 II 期研究。
Adv Ther. 2020 May;37(5):2288-2302. doi: 10.1007/s12325-020-01310-4. Epub 2020 Apr 15.
7
The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study.标准化相角在成人急性白血病中的预后价值:一项前瞻性研究。
Cancer Med. 2020 Apr;9(7):2403-2413. doi: 10.1002/cam4.2835. Epub 2020 Feb 12.
8
Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care.为老年血液恶性肿瘤患者提供强化治疗:个性化护理策略。
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):63-70. doi: 10.1182/hematology.2019001300.
9
Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling.为老年急性髓系白血病患者制定个体化治疗方案:老年评估和基因谱分析的作用。
Cancer Treat Rev. 2019 May;75:52-61. doi: 10.1016/j.ctrv.2019.04.001. Epub 2019 Apr 11.
10
Endurance and resistance training in patients with acute leukemia undergoing induction chemotherapy-a randomized pilot study.诱导化疗期间急性白血病患者的耐力和抗阻训练:一项随机试验研究。
Support Care Cancer. 2019 Mar;27(3):1071-1079. doi: 10.1007/s00520-018-4396-6. Epub 2018 Aug 18.

本文引用的文献

1
Drug therapy for acute myeloid leukemia.急性髓系白血病的药物治疗
Blood. 2005 Aug 15;106(4):1154-63. doi: 10.1182/blood-2005-01-0178. Epub 2005 May 3.
2
Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.对于接受统一强化治疗的60岁及以上急性髓系白血病患者,疾病生物学而非年龄是生存的最重要决定因素。
Cancer. 2005 May 15;103(10):2082-90. doi: 10.1002/cncr.21006.
3
Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG).老年急性髓系白血病患者:生物学、患者及治疗特征。德国血液学和肿瘤学会(DGHO)、奥地利血液学和肿瘤学会(OGHO)以及德国老年医学学会(DGG)老年肿瘤学工作组的建议
Onkologie. 2004 Feb;27(1):72-82. doi: 10.1159/000075610.
4
Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome.老年急性髓系白血病或晚期骨髓增生异常综合征患者的决策制定与生活质量
Leukemia. 2004 Apr;18(4):809-16. doi: 10.1038/sj.leu.2403289.
5
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).预处理细胞遗传学异常可预测初发急性髓系白血病成年患者的诱导缓解成功率、累积复发率及总生存期:癌症与白血病B组研究结果(CALGB 8461)
Blood. 2002 Dec 15;100(13):4325-36. doi: 10.1182/blood-2002-03-0772. Epub 2002 Aug 1.
6
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.老年急性髓系白血病(AML)患者中细胞遗传学分层分类的预测价值:对纳入英国医学研究委员会AML11试验的1065例患者的分析
Blood. 2001 Sep 1;98(5):1312-20. doi: 10.1182/blood.v98.5.1312.
7
Managing therapy in older adult patients with acute myeloid leukemia.
Semin Hematol. 2001 Jul;38(3 Suppl 6):10-6. doi: 10.1016/s0037-1963(01)90151-9.
8
Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia.急性髓细胞白血病诱导化疗强化程度增加时的失败模式。
Br J Haematol. 2001 Jun;113(3):727-36. doi: 10.1046/j.1365-2141.2001.02756.x.
9
How I treat older patients with AML.我如何治疗老年急性髓系白血病患者。
Blood. 2000 Sep 1;96(5):1670-3.
10
Management of acute myeloid leukemia in elderly patients.老年急性髓系白血病的管理
J Clin Oncol. 1999 Nov;17(11):3569-76. doi: 10.1200/JCO.1999.17.11.3569.

急性髓系白血病患者的功能状态损害与生存情况

Impairment in functional status and survival in patients with acute myeloid leukaemia.

作者信息

Wedding Ulrich, Röhrig Bernd, Klippstein Almuth, Fricke Hans-Joerg, Sayer Herbert G, Höffken Klaus

机构信息

Clinic for Internal Medicine II, Department of Hematology and Medical Oncology, Friedrich Schiller University, Erlanger Allee 101, 07747, Jena, Germany.

出版信息

J Cancer Res Clin Oncol. 2006 Oct;132(10):665-71. doi: 10.1007/s00432-006-0115-7. Epub 2006 Jul 5.

DOI:10.1007/s00432-006-0115-7
PMID:16821071
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12161015/
Abstract

Acute myeloid leukaemia (AML) is mainly affecting elderly patients. Elderly patients are increasingly affected by impairment of functional status (FS). FS is of prognostic relevance for survival in different tumours. Data for patients with AML are rare. Within a prospective trial we recruited patients with newly diagnosed AML and measured FS by two different methods: Karnofsky performance status (KPS) and instrumental activities of daily living (IADL). Sixty-three patients aged 19-85 years (median 61.1) were included. Twenty-three had prior myelodisplastic syndrome (MDS), 7 favourable, 17 unfavourable karyotype. Fifty received induction chemotherapy, 13 palliative chemotherapy. Median survival was 15.2 months (95% CI, 10.8-22.3) in all patients. Age, cytogenetic risk group, and impaired KPS and IADL significantly influenced median survival in univariate analysis. Impairment of IADL was the single most predictive variable. In multivariate analysis, impairment of IADL Score (HR:4.3, 95% CI 1.7-10.5, P = 0.001) and of KPS (HR:4.8, 95% CI 1.9-12.3, P = 0.001), and unfavourable cytogenetic risk group (HR:6.0, 95% CI 2.5-14.3, P < 0.001) significantly predicted median survival. In patients with AML, FS and not age is a major predictor of survival. The influence of FS is independent from cytogenetic risk group. IADL measurement adds information to KPS. The results have to be confirmed in a large sample of patients.

摘要

急性髓系白血病(AML)主要影响老年患者。老年患者越来越多地受到功能状态(FS)损害的影响。FS对不同肿瘤的生存具有预后相关性。AML患者的数据很少。在一项前瞻性试验中,我们招募了新诊断的AML患者,并通过两种不同方法测量FS:卡诺夫斯基表现状态(KPS)和日常生活工具性活动(IADL)。纳入了63例年龄在19 - 85岁(中位数61.1岁)的患者。23例曾患骨髓增生异常综合征(MDS),7例核型良好,17例核型不良。50例接受诱导化疗,13例接受姑息化疗。所有患者的中位生存期为15.2个月(95%CI,10.8 - 22.3)。在单因素分析中,年龄、细胞遗传学风险组以及KPS和IADL受损显著影响中位生存期。IADL受损是唯一最具预测性的变量。在多因素分析中,IADL评分受损(HR:4.3,95%CI 1.7 - 10.5,P = 0.001)、KPS受损(HR:4.8,95%CI 1.9 - 12.3,P = 0.001)以及不良细胞遗传学风险组(HR:6.0,95%CI 2.5 - 14.3,P < 0.001)显著预测中位生存期。在AML患者中,FS而非年龄是生存的主要预测因素。FS的影响独立于细胞遗传学风险组。IADL测量为KPS增加了信息。这些结果必须在大量患者样本中得到证实。